Onzima Ventures to buy remaining stake in drug discovery company

Maryam Cockar Sharecast | 13 Apr, 2017 09:11 | | |

pills tablets medicine drugs pharmaceutical
  • 9.25
  • 1.37%0.13
  • Max: 9.37
  • Min: 9.09
  • Volume: 625,728
  • MM 200 : n/a
17:18 26/05/17
  • 2,125.43
  • 0.29%6.19
  • Max: 2,132.49
  • Min: 2,118.00
  • Volume: 0
  • MM 200 : n/a
17:30 26/05/17
  • 991.38
  • 0.23%2.28
  • Max: 991.65
  • Min: 989.25
  • Volume: 0
  • MM 200 : n/a
17:19 26/05/17

AIM-listed investor Onzima Ventures is to buy the remaining 51% stake it does not already own in N4 Pharma, a drug discovery company, subject to shareholder approval.

At the next general meeting on 2 May, the company will also propose change its name to N4 Pharma, and if approved its ticker will be changed to N4P and its website address to www.n4pharma.com.

The company will pay for the interest with issue of 4.51m new shares and 4,59m deferred shares to be issued after the reorganisation of its shares. The new shares expected to trade on AIM on 3 May.

Onzima has also raised £1.5m from a placing of 21.42m shares at 7p each to fund development of additional patent applications for reformulations of a range of generic drugs, to undertake clinical trials for N4 Pharma's reformulation of sildenafil, the medical name for generic Viagra.

N4 Pharma chief executive Nigel Theobald said: "Bringing a new drug to market is inherently risky, time consuming and extremely costly. However, the established process of reformulating already established drugs reduces the risk, cost and length of time it takes to bring new versions of these drugs to market.

“Following completion of the transaction, the net funds raised will enable N4 Pharma to accelerate its work on the reformulation of generic drugs and those that are coming to the end of their patent protection, each with attractive commercial opportunities, as well as expand our product portfolio.”

More news

26 May Europe close: Markets slip as uncertainty around Brexit ramps up

European stocks limped into the weekend, weighed down by an overnight drop in the price of oil and with investors carefully monitoring events ahead of the UK elections.

26 May Director dealings: DMGT trio buy after results disappointment

Daily Mail and General Trust chairman Lord Rothermere and his new CEO and CFO bought £0.3m of shares on Friday, following disappointing interim results the day before.

26 May FX round-up: Sterling takes big slides lower on UK election uncertainty

Sterling took big slides lower on most major crosses Friday as political uncertainty surrounding the upcoming UK general election sparked a wave of selling.

26 May Avingtrans' Hayward Tyler takeover talks extended until June

Talks about a potential takeover of Hayward Tyler by Avingtrans will continue after the pair further pushed back the official deadline.

26 May Acacia Mining fights back against Tanzania discrepancy claims

Firing back a response to Tanzanian accusations that it under-declared gold exports, Acacia Mining has called for an independent review and said "we are considering all of our options".

26 May Europe midday: Oil price drop, currency volatility dampens sentiment

European stocks are under pressure heading into the end of the week, weighed down by an overnight drop in the price of oil and with investors carefully monitoring events ahead of the UK elections.

26 May Plastics Capital raises £3.7m in placing

Niche plastics products group Plastics Capital announced a conditional placing to raise approximately £3.74m before expenses on Friday, by way of a placing of 3,194,445 new ordinary shares at 117p per placing share.

26 May SafeCharge partners with Chase for US payments

Payments technology company SafeCharge announced a partnership to process payments in the United States through Chase on Friday.

26 May US GDP grows more quickly than expected in the first quarter

America's economy grew more quickly than expected at the start of the year amid a large increase in investment, revised data showed.

26 May RBS shareholders refuse to accept settlement

Royal Bank of Scotland was further frustrated in its attempts to settle with a shareholder action group claiming compensation over its 2008 rights issue, following several delays to the start of its High Court trial.